Pipeline

1) Partner with Eisai on BAN2401 for treatment of Alzheimer’s disease. Eisai partnered with Biogen on BAN2401 in 2014

2) Dementia and cognitive impairment associated with Down’s syndrome and Traumatic Brain Injury

3) AbbVie in-licensed BAN0805 in late 2018 and will continue to develop the antibody, now with the designation ABBV-0805

BioArctic’s portfolio has projects in several therapy areas and in various phases from discovery to clinical development. Project portfolio per March 31, 2019.